TECHWIRE 30
(CIX: WRAL30)  1,085.92  up arrow+9.26  (0.86 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Apple)  105.22  up arrow+0.39  (0.37 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: QUINTILES)  57.56  up arrow+0.57  (1 %)  Updated: 06:40 PM EDT, Oct 24 2014
(OP: BASF SE)  87.22  down arrow-2.43  (-2.71 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: BioCryst)  11.83  down arrow-0.36  (-2.95 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: BioDelivery)  16.62  up arrow+0.24  (1.47 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: CEMP)  12.46  up arrow+0.14  (1.14 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Cisco Systems)  23.78  up arrow+0.22  (0.91 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Cree)  29.67  up arrow+0.27  (0.92 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: DARA)  0.87  down arrow-0.03  (-3.34 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: EMC CORPORATION)  28.17  up arrow+0.47  (1.7 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: Extreme Networks)  3.14  up arrow+0.02  (0.64 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: FB)  80.67  up arrow+0.63  (0.79 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: GLAXOSMITHKLINE)  45.79  up arrow+0.43  (0.95 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: GOOG)  539.78  down arrow-4.2  (-0.77 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: IBM)  162.08  down arrow-0.1  (-0.06 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NY: LH)  103.73  up arrow+1.05  (1.02 %)  Updated: 06:40 PM EDT, Oct 24 2014
(OP: Lenovo Group)  29.09  up arrow+0.07  (0.24 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: MRK)  57.61  up arrow+0.98  (1.73 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: Microsoft Corp)  46.13  up arrow+1.11  (2.47 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: NTAP)  40.72  up arrow+0.42  (1.04 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: NOVARTIS AG)  90.15  up arrow+0.91  (1.02 %)  Updated: 06:40 PM EDT, Oct 24 2014
(OP: Novozymes A/S)  44.71  up arrow+0.17  (0.38 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: PFIZER)  29.11  up arrow+0.51  (1.78 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: Pozen)  8.75    (0 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: RED HAT)  56.02  up arrow+0.51  (0.92 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: BBRY)  10.26  down arrow-0.06  (-0.53 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Salix)  140.42  up arrow+4.86  (3.59 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: SQI)  15.60  up arrow+0.08  (0.52 %)  Updated: 08:10 PM EDT, Oct 24 2014

Posts tagged “Biotech & Life Science”

3:11 p.m. Friday

#WTWTrends for Friday: Ebola, Zuckerberg speaks Chinese, UNC, SA101, Seattle Shooting Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Friday, Oct. 24, 2014 as curated by @WRALTechWire.

Updated 2:35 p.m. Friday

GSK exec on Ebola vaccine trial: 'We only have one shot to get this right'

Ebola The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?

9:55 a.m. Wednesday

Witty defends himself, GSK: 'Look at what we're able to achive'

Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

6:02 a.m. Wednesday

Premium Lock Viamet Pharma withdaws IPO, raises $60M, names Bob Ingram chairman

Viamet Pharmaceuticals scrapped its plans for a $75 million IPO on Tuesday. Instead, the Triangle-based company raised $60 million in new capital. At the same time Viamet named former Glaxo CEO Bob Ingram as its chairman and spun off a new venture focused on prostate cancer.

Robert Ingram Robert Ingram

3:07 p.m. Tuesday

GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

2:28 p.m. Tuesday

NC Biotech Center awards $885,000 in grants, loans across state

Biotech During the same period, the Center determined that more than $13 million in outside funding was raised by companies previously awarded NCBiotech loans.

7:09 a.m. Tuesday

Red Hat-SAP mobile deal; Microsoft CEO earns $84M; LabCorp's new HIV test; NC falls to 3rd in biz climate; Honda Aircraft expands

Bulldog In today's Bulldog wrapup of life science and technology news: Red Hat and SAP partner in the cloud; Microsoft's CEO earns $84 million pay package; LabCorp launches new HIV test; North Carolina slips in a business climate survey; and Honda Aircraft keeps growing in the Triad.

3:32 p.m. Monday

#WTWTrends for Monday: DeSimone, IBM, Raleigh, NC State Fair Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Monday, Oct. 20, 2014 as curated by @WRALTechWire.

7:01 a.m. Monday

Review: Your 58 WRAL TechWire headlines from last week

Week in review Some local websites run one or two tech stories per day. Others a few more but mixed with a variety of business news. At WRAL TechWire, tech and life science make up the menu with more than 50 stories published over the last five business days. Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week.

6:59 a.m. Monday

Have news? Share it with WRAL TechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

Updated October 17

Exec: GSK's Ebola vaccine will 'come too late' for current epidemic

Ebola The head of Ebola vaccine research at GlaxoSmithKline tells the BBC that the company's treatment that is now being tested isn't likely to be "the primary answer to this particular outbreak." He concedes GSK could have moved faster.

October 17

NC award for Bob Ingram; CED's parties; Amazon hiring 80,000; AMD layoffs; FBI warns on phone encryption

Bulldog In today's Bulldog wrapup on technology and life science news: Former GSK exec Bob Ingram to receive NC honor; the CED plans 30th anniversary parties; Amazon is hiring big time; AMD is cutting jobs; and the FBI director warns against cellphone encryption.

Updated October 16

Durham-based Chimerix speeds up Ebola testing

Ebola Chimerix says it has FDA approval to launch a Phase 2 clinical trial of its possible treatment for Ebola. The drug has already been administered to two Ebola patients, one of whom died. The new trial will test safety, tolerability and efficacy for Brincidofovir.

October 16

LabCorp-LipoScience deal advances; Red Hat's new women awards; a comet landing; eBay's miss; NetFlix plunge

Bulldog In today's wrapup of tech and life science news: LabCorp's $85M acquisition of LipoScience clears a key hurdle; Red Hat announces women in Open Source awards; a comet landing is at hand; eBay's miss; and NetFlix stock plunges.

October 15

AskBio, spinouts tackle big diseases with nano technology

AskBio founder R. Jude Samulski, Ph.D. Hemophilia. Duchenne muscular dystrophy. Epilepsy. Alzheimer's disease. Diabetic retinopathy. Age-related macular degeneration. Osteoarthritis. These are just some of the diseases that Chapel Hill-based Asklepios BioPharmaceutical (AskBio) is working to alleviate through the development and delivery of novel, intracellular protein therapeutics using its cutting-edge Biological Nano Particle (BNP) technology.

October 14

Entegrion lands $7.8M from DoD; Zuckerbergs donate $25M for Ebola fight; Bioventus acquires product line; Yelp fights extortion claims

Bulldog In today's Bulldog wrapup of life science and technology news: Entegrion lands $7.8 million Department of Defense contract for platelet development; Zuckerbergs donate to fight Ebola; Bioventus acquires a product line; Yelp fights extortion claims.

October 14

Bioterror threat: 'If I want to attack somebody nowadays, all I need is a plane ticket to an international destination'

Bioterror  At the first "Bio Defense Summit, leaders from across North Carolina discuss the threats of bioterror and how N.C. can secure more federal research and development funds to help head off any future attack on the U.S. The Ebola epidemic has only increased concerns about what a bioterror attack could mean.

October 13

Dallas health worker tests positive for Ebola

Ebola A "breach of protocol" at the hospital where Ebola victim Thomas Eric Duncan was treated before his death led to the infection of a health care worker with the deadly virus, and other caregivers could potentially be exposed, federal health officials said Sunday.

Updated October 13

Making news? Share it with WRAL TechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

October 13

Your 55 WRAL TechWire headlines from last week

Week in review Some local websites run one or two tech stories per day. Others a few more but mixed with a variety of business news. At WRAL TechWire, tech and life science make up the menu with more than 50 stories published over the last five business days. Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll